-
1 Comment
Optiscan Imaging Limited is currently in a long term uptrend where the price is trading 14.6% above its 200 day moving average.
From a valuation standpoint, the stock is 14.8% more expensive than other stocks from the Technology sector with a price to sales ratio of 82.0.
Optiscan Imaging Limited's total revenue rose by 60.4% to $534K since the same quarter in the previous year.
Its net income has increased by 37.5% to $-752K since the same quarter in the previous year.
Finally, its free cash flow grew by 81.9% to $-91K since the same quarter in the previous year.
Based on the above factors, Optiscan Imaging Limited gets an overall score of 4/5.
| ISIN | AU000000OIL4 |
|---|---|
| Sector | Technology |
| Industry | Scientific & Technical Instruments |
| CurrencyCode | AUD |
| Exchange | AU |
| Target Price | None |
|---|---|
| PE Ratio | 0.0 |
| Market Cap | 66M |
| Dividend Yield | 0.0% |
| Beta | 1.81 |
Optiscan Imaging Limited develops and commercializes confocal microscopes for clinical and pre-clinical applications in Australia, Germany, and Internationally. It offers FIVE2 (ViewnVivo) system, a miniaturized confocal endomicroscopes use for clinical, translational, pre-clinical, and other research. The company also engages in the development of InVivage device for use in cancer screening and surgery. Optiscan Imaging Limited was founded in 1994 and is headquartered in Mulgrave, Australia.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for OIL.AU using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
